Modus Advisors LLC Takes $41,000 Position in iShares Biotechnology ETF (NASDAQ:IBB)

Modus Advisors LLC bought a new position in iShares Biotechnology ETF (NASDAQ:IBB) in the 4th quarter, Holdings Channel reports. The fund bought 313 shares of the financial services provider’s stock, valued at approximately $41,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IBB. Darwin Wealth Management LLC bought a new stake in iShares Biotechnology ETF during the third quarter valued at about $29,000. Highline Wealth Partners LLC purchased a new stake in shares of iShares Biotechnology ETF during the third quarter worth about $30,000. Ashton Thomas Securities LLC bought a new stake in iShares Biotechnology ETF during the 3rd quarter valued at approximately $36,000. Voisard Asset Management Group Inc. purchased a new position in iShares Biotechnology ETF in the 3rd quarter worth approximately $59,000. Finally, Aptus Capital Advisors LLC boosted its stake in iShares Biotechnology ETF by 36.5% in the 3rd quarter. Aptus Capital Advisors LLC now owns 426 shares of the financial services provider’s stock worth $62,000 after purchasing an additional 114 shares during the period. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 0.9 %

Shares of IBB opened at $134.15 on Friday. iShares Biotechnology ETF has a 1 year low of $123.60 and a 1 year high of $150.57. The company has a 50 day simple moving average of $138.72 and a two-hundred day simple moving average of $142.01.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, December 20th. Investors of record on Tuesday, December 17th were paid a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.